Assessing Real World Efficacy, Safety, and 18-Month Retention Rates of Cannabidiol in Individuals With Drug Resistant Epilepsies.

ABSTRACT:

Background

Highly purified Cannabidiol (CBD, epidiolex) is approved for treating Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis (TSC), with off-label use in drug-resistant epilepsies. The aim of this study is to evaluate efficacy, safety, and long-term retention of CBD in a large pediatric population.

Methods

We prospectively included all consecutive patients initiating CBD for drug-resistant epilepsy at our pediatric tertiary center from 2019 to 2021. Efficacy and safety were assessed via parental questionnaires on seizure and non-seizure outcomes at 1, 2, and 6 months, comparing each item to prior clinic visits. Retention rate was evaluated at 18 months.

Results

We included 103 patients (mean age 11.2 years), with 47% receiving CBD for l

SUBMITTER: Chemaly N 

PROVIDER: S-EPMC12446575 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature